Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensified Adjuvant Therapy for High-Risk Newly Diagnosed Glioblastoma
NCT07670026Phase 2
Key facts
- Status
- Recruiting
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Countries
- 1
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Conditions
- glioblastoma (GBM)
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and bevacizumab in glioblastoma (GBM), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Progression-Free Survival at 2 years. Started Dec 2025; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Sintilimab plus Bevacizumab
Single arm receiving concurrent chemoradiotherapy followed by adjuvant temozolomide, sintilimab, and bevacizumab.
03
Who it enrols
Adults with pathologically confirmed glioblastoma who have undergone subtotal resection or have short-term progression before radiotherapy, with adequate organ function and no prior brain radiotherapy.
04
Endpoints
Primary
Progression-Free Survival
Secondary
Overall Survival
Quality of life accessed by EORTC-QLQ-C30
Incidence of Treatment-Emergent Adverse Events
Beyond the preview
Go deeper on NCT07670026.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07670026.